ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million

Stock Information for ABVC BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ABVC BioPharma Inc.

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.